Eli Lilly, Novo Nordisk Shares Fall on CVS Medicare Decision

CVS Health announced it will opt out of the Medicare obesity drug coverage model, affecting reimbursement for weight‑loss medications.
Eli Lilly shares dropped 3.8% following the CVS decision.
Novo Nordisk shares fell over 4.3% after the same announcement.
The move highlights uncertainty around Medicare coverage for obesity treatments, potentially impacting market sentiment for weight‑loss drug makers.